Phase 3
Completed N=706
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
Source: ClinicalTrials.gov NCT04068051 ↗Enrolled (actual)
706
Serious AEs
1.1%
Results posted
Oct 2023
Primary outcomePrimary: Long-term Safety of Chronic Intermittent Use of AXS-07 — 293; 118; 8; 10 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
MOVEMENT (Multimechanistic Treatment over Time of Migraine Symptoms) is a Phase 3 study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess the effect of AXS-07 on migraine symptoms following repeated treatment of migraine attacks.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Long-term Safety of Chronic Intermittent Use of AXS-07 |
293; 118; 8; 10; 13; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Has participated in a prior study with AXS-07 for the treatment of migraine
Exclusion Criteria
- Has previously received any investigational drug or device or investigational therapy within 30 days before Screening, other than AXS-07
- Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
Data sourced from ClinicalTrials.gov (NCT04068051). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.